Aequus Pharmaceuticals (Aequus Pharmaceuticals) 3-Year Revenue Growth Rate : -20.60% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals 3-Year Revenue Growth Rate?

Aequus Pharmaceuticals's Revenue per Share for the three months ended in Sep. 2023 was $0.00.

During the past 12 months, Aequus Pharmaceuticals's average Revenue per Share Growth Rate was -50.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -20.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of Aequus Pharmaceuticals was 18.10% per year. The lowest was -20.60% per year. And the median was 6.75% per year.

Competitive Comparison of Aequus Pharmaceuticals's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aequus Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

Aequus Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Aequus Pharmaceuticals (OTCPK:AQSZF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Aequus Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

AEQ:Germany AQS:Canada

Address

200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4

Website

https://www.aequuspharma.ca

Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.